The Food and Drug Administration (FDA) has updated the prescribing information for Nuplazid® (pimavanserin; Acadia Pharmaceuticals) to include additional administration instructions for patients who have difficulty swallowing the whole capsule.

Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. In addition to being swallowed whole, the updated labeling now states that the contents of Nuplazid capsules can be sprinkled over a tablespoon (15mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. The drug/food mixture must be consumed immediately without chewing and should not be stored for future use. 

The capsules are supplied as 34mg of pimavanserin in 30-count bottles. Nuplazid is also available as 10mg film-coated tablets in 30-count bottles.

For more information visit


Nuplazid® [package insert]. San Diego, CA: Acadia Pharmaceuticals Inc; 2020.